Companies › Curium US
2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Oncology; next expected readout Feb 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 177Lu-PSMA-I&T Lutetium-177 labeled PSMA-targeting radioligand therapy | PSMA | Phase 3 | Metastasis From Malignant Tumor of Prostate; Prostate Cancer | Feb 2029 |
| Copper Cu 64 PSMA I&T Cu-64 labeled PSMA-targeting radiopharmaceutical for PET imaging | FOLH1 | Phase 3 | Prostate Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06235151 | Copper Cu 64 PSMA I&T | Phase 3 | Prostate Cancer | Oncology | Oct 2026 |
| NCT04886986 | 177Lu-PSMA-I&T | Phase 1 | Prostate Cancer | Oncology | Dec 2027 |
| NCT05204927 | 177Lu-PSMA-I&T | Phase 3 | Metastasis From Malignant Tumor of Prostate | Oncology | Feb 2029 |
Clarity Pharmaceuticals Fusion Pharmaceuticals POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company ABX advanced biochemical compounds FutureChem
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.